Physician profile
Robert J Cooper
NPI 1992739726
$106,265.68
in general payments reported to CMS, 2019-2025
51 companies · $42K in 2025
The $42K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,860 · 2021: $10K · 2022: $2,485 · 2023: $17K · 2024: $2,104 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Consulting Fee: $5,870 · Food and Beverage: $5,694 · Travel and Lodging: $3,978 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,576.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,862.50 |
| Consulting Fee | $5,870.00 |
| Food and Beverage | $5,694.20 |
| Travel and Lodging | $3,978.38 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $24,785.40 | 2022-2025 | Yorvipath |
| Abbott Laboratories | $21,146.68 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $13,006.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $12,258.12 | 2019-2025 | Evenity, Prolia, Repatha |
| Shire North American Group INC | $11,430.31 | 2019 | |
| Horizon Therapeutics Plc | $5,740.98 | 2019-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $3,284.94 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $1,871.04 | 2021-2023 | Recorlev |
| Strongbridge US INC. | $1,800.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $1,709.62 | 2021-2025 | Strensiq |
| Novo Nordisk INC | $1,069.84 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Amryt Pharma Holdings Ltd | $825.59 | 2022-2023 | Mycapssa |
| Janssen Pharmaceuticals, INC | $725.26 | 2019 | |
| Becton, Dickinson and Company | $648.92 | 2021 | |
| Tersera Therapeutics LLC | $620.00 | 2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $616.49 | 2019-2024 | |
| Mannkind Corporation | $494.71 | 2019-2024 | Afrezza |
| Tandem Diabetes Care, INC. | $486.88 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $422.43 | 2023-2024 | Synthroid |
| Zoll Medical Corporation | $413.33 | 2019 | |
| Radius Health, INC. | $363.64 | 2022-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $352.49 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.79 | 2020-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $253.40 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $184.08 | 2019-2020 | |
| Genzyme Corporation | $181.00 | 2019-2020 | |
| Antares Pharma, INC. | $175.48 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Cequr Corporation | $160.31 | 2022-2025 | Cequr Simplicity |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Vistapharm, INC. | $85.09 | 2021 | |
| Recordati_rare_diseases_inc. | $77.88 | 2022-2023 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $59.25 | 2019 | |
| Pfizer INC. | $58.59 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $52.23 | 2024 | |
| Merck Sharp & Dohme LLC | $50.73 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $45.50 | 2022-2025 | |
| Nevro Corp. | $37.36 | 2022-2023 | Senza |
| Medtronic, INC. | $36.72 | 2022-2023 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $32.22 | 2021-2022 | |
| Sequel Med Tech, LLC | $29.60 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $29.16 | 2023 | Imcivree |
| Corcept Therapeutics | $26.38 | 2023 | Korlym |
| Insulet Corporation | $25.57 | 2024 | Omnipod |
| Kyowa Kirin, INC. | $25.48 | 2023 | Crysvita |
| Amneal Pharmaceuticals LLC | $23.74 | 2024 | Unithroid |
| Beta Bionics, INC. | $21.78 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ipsen Biopharmaceuticals, INC | $21.49 | 2019 | |
| Astellas Pharma US INC | $20.53 | 2023 | Veozah |
| Amphastar Pharmaceuticals, INC. | $17.98 | 2024 | Baqsimi |
| Eusa Pharma (US) LLC | $14.63 | 2022 | |
| Echosens North America, INC. | $10.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.